Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.

Figure 3 illustrates that the symptom severity score in the asciminib arm showed a trend to decrease after starting asciminib treatment and that symptoms remained stable throughout asciminib treatment (a decrease in symptoms relates to improvement).

also in 53,322 other papers

Patients in the asciminib arm maintained or showed a decreasing trend in severity in all individual MDASI-CML symptom items (demonstrating decreasing severity in 15 out of 20 symptoms); the most notable decreases in symptom severity reported in the overall timeframe were in the symptoms of fatigue (which was the highest at baseline) and having a dry mouth, although these decreases in scores were not clinically meaningful (Supplementary Table S2 ).

also in 47,180 other papers